Moreover, blocking antibodies against CCL2 have been investigated in a variety of disease models in vivo, e.g., in hepatocellular cancer, where intraperitoneal (i.p.)injection of an anti-CCL2 antibody reduced inflammatory myeloid cells in the liver compared to control, or in a zymosan-induced peritonitis model, where coadministration of an anti-CCL2 antibody with zymosan i.p. significantly reduced monocyte accumulation in the peritoneal cavity (60). The gene discussed is CCL2; the disease is hepatocellular carcinoma.